With 0.71 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.58 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $25.47 whereas the lowest price it dropped to was $24.01. The 52-week range on ARVN shows that it touched its highest point at $53.08 and its lowest point at $21.17 during that stretch. It currently has a 1-year price target of $63.25. Beta for the stock currently stands at 1.83.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ARVN was up-trending over the past week, with a rise of 1.65%, but this was down by -9.40% over a month. Three-month performance dropped to -1.21% while six-month performance fell -6.47%. The stock lost -28.02% in the past year, while it has lost -40.26% so far this year. A look at the trailing 12-month EPS for ARVN yields -4.67 with Next year EPS estimates of -4.72. For the next quarter, that number is -0.96. This implies an EPS growth rate of 52.40% for this year and -49.80% for next year. EPS is expected to decline by -3.50% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 23.62%.
Float and Shares Shorts:
At present, 68.70 million ARVN shares are outstanding with a float of 59.52 million shares on hand for trading. On 2024-11-29, short shares totaled 9.02 million, which was 1313.0 higher than short shares on 1730332800. In addition to Dr. John G. Houston Ph.D. as the firm’s Chairperson, CEO & President, Dr. Ian Taylor Ph.D. serves as its President of Research & Development and Chairman of Scientific Advisory Board.
Institutional Ownership:
Through their ownership of 1.09262 of ARVN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, ARVN reported revenue of $102400000.0 and operating income of -$60300000.0. The EBITDA in the recently reported quarter was -$58700000.0 and diluted EPS was -$0.68.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ARVN since 13 analysts follow the stock currently. There are 11 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 2 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With ARVN analysts setting a high price target of 110.0 and a low target of 28.0, the average target price over the next 12 months is 63.25. Based on these targets, ARVN could surge 347.34% to reach the target high and rise by 13.87% to reach the target low. Reaching the average price target will result in a growth of 157.22% from current levels.
Analysts have provided yearly estimates in a range of -$2.31504 being high and -$4.36522 being low. For ARVN, this leads to a yearly average estimate of -$3.15865. The surprise factor in the prior quarter was -$0.59. Based on analyst estimates, the high estimate for the next quarter is -$0.96 and the low estimate is -$1.64. The average estimate for the next quarter is thus -$1.32.
